Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Su J, Song C, Si Y, Cui L, Yang T, Li Y, Wang H, Tai G, Zhou Y.
Identification of key amino acid residues determining ligand binding specificity, homodimerization and cellular distribution of human galectin-10. Glycobiology 2019

Persson E, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier J, Deswarte K, Verschueren K, Dansercoer A, Gras D, Chanez P, Bachert C, Gonçalves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides S, Lambrecht B.
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science (New York, N.Y.) 2019

Persson E, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier J, Deswarte K, Verschueren K, Dansercoer A, Gras D, Chanez P, Bachert C, Gonçalves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides S, Lambrecht B.
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science (New York, N.Y.) 2019

Persson E, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier J, Deswarte K, Verschueren K, Dansercoer A, Gras D, Chanez P, Bachert C, Gonçalves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides S, Lambrecht B.
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science (New York, N.Y.) 2019

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Su J, Gao J, Si Y, Cui L, Song C, Wang Y, Wu R, Tai G, Zhou Y.
Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology 2017

Ackerman SJ, Liu L, Kwatia MA, Savage MP, Leonidas DD, Swaminathan GJ, Acharya KR
Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion J. Biol. Chem. 2002

Ackerman, S. J., Liu, L., Kwathia M.A., Savage,M..P., Leonidas, D. D., Swaminathan, G. J., Acharya, K. R.
Charcot-Leyden crystal protein (Galectin-10) is not a dual-function galectin with lysophospholipase but binds a lysophospholipase inhibitor in a novel structural fashion J. Biol. Chem. 2002

Swaminathan, G.J., Leonidas, D.D., Savage, M.P., Ackerman, S.J., Acharya, K.R.
Selective recognition of mannose by the human eosinophil charcot-leyden crystal protein (Galectin-10): a crystallographic study at 1.8 A resolution Biochemistry 1999

Leonidas, D.D., Elbert, B.L., Zhou, Z., Leffler, H., Ackerman, S.J., Acharya, K.R.
Crystal structure of human charcot-leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of galectins Structure 1995